Randomized Trial of the Effects of Risedronate on Vertebral Fractures in Women with Established Postmenopausal Osteoporosis
The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
The purpose of this randomized, double-masked, placebo-controlled study was to determine the efficacy and safety of risedronate in the prevention of vertebral fractures in postmenopausal women with established osteoporosis. The study was conducted at 80 study centers in Europe and Australia. Postmenopausal women (n = 1226) with two or more prevalent vertebral fractures received risedronate 2.5 or 5 mg/day or placebo; all subjects also received elemental calcium 1000 mg/day, and up to 500 IU/day vitamin D if baseline levels were low. The study duration was 3 years; however, the 2.5 mg group was discontinued by protocol amendment after 2 years. Lateral spinal radiographs were taken annually for assessment of vertebral fractures, and bone mineral density was measured by dual-energy X-ray absorptiometry at 6-month intervals. Risedronate 5 mg reduced the risk of new vertebral fractures by 49% over 3 years compared with control (p<0.001). A significant reduction of 61% was seen within the first year (p = 0.001). The fracture reduction with risedronate 2.5 mg was similar to that in the 5 mg group over 2 years. The risk of nonvertebral fractures was reduced by 33% compared with control over 3 years (p = 0.06). Risedronate significantly increased bone mineral density at the spine and hip within 6 months. The adverse-event profile of risedronate, including gastrointestinal adverse events, was similar to that of control. Risedronate 5 mg provides effective and well-tolerated therapy for…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This is true for fracture patients with BMD in both the low bone mass and osteoporosis range [49–58].”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [52]
In the citing paper
“There is abundant evidence that the elevated risk of fracture in patients with osteoporosis by BMD is reduced with pharmacotherapy [52, 57, 59–70].”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [52]
In the citing paper
“There are abundant data that patients with spine and hip fractures will have reduced fracture risk if treated with pharmacologic therapy.”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [52]
In the citing paper
“Risedronate reduces the incidence of vertebral fractures by 41 to 49 % and nonvertebral fractures by 36 % over 3 years, with significant risk reduction occurring within 1 year of treatment in patients with a prior vertebral fracture [51, 52].”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [52]
In the citing paper
“Risedronate reduces the incidence of vertebral fractures by 41 to 49 % and nonvertebral fractures by 36 % over 3 years, with significant risk reduction occurring within 1 year of treatment in patients with a prior vertebral fracture [51, 52].”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [52]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Black, D. M., Cummings, S. R., Karpf, D. B., Cauley, J. A., Thompson, D. E., Nevitt, M. C., Bauer, D. C., Genant, H. K., Haskell, W. L., Marcus, R., et al. (1996) · The Lancet · doi:10.1016/s0140-6736(96)07088-2 · Cited by 3,846
Vertebral fracture assessment using a semiquantitative technique
Genant, H. K., Wu, C. Y., van Kuijk, C., & Nevitt, M. C. (1993) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650080915 · Cited by 3,691
Treatment of Postmenopausal Osteoporosis with Transdermal Estrogen
Lufkin, E. G., Wahner, H. W., O'Fallon, W. M., Hodgson, S. F., Kotowicz, M. A., Lane, A. W., Judd, H. L., Caplan, R. H., & Riggs, B. L. (1992) · Annals of Internal Medicine · doi:10.7326/0003-4819-117-1-1 · Cited by 810
Estrogen Replacement Therapy and Fractures in Older Women
Cauley, J. A., Seeley, D. G., Ensrud, K., Ettinger, B., Black, D., Cummings, S. R., & and For The Study of Osteoporotic Fractures Research Group* (1995) · Annals of Internal Medicine · doi:10.7326/0003-4819-122-1-199501010-00002 · Cited by 809
Serum vitamin D concentrations among elderly people in Europe
van der Wielen, R. P. J., de Groot, L. C. P. G. M., van Staveren, W. A., Löwik, M. R. H., van den Berg, H., Haller, J., & Moreiras, O. (1995) · The Lancet · doi:10.1016/s0140-6736(95)91266-5 · Cited by 772
Esophagitis Associated with the Use of Alendronate
de Groen, P. C., Lubbe, D. F., Hirsch, L. J., Daifotis, A., Stephenson, W., Freedholm, D., Pryor-Tillotson, S., Seleznick, M. J., Pinkas, H., & Wang, K. K. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351403 · Cited by 764
Treatment of Postmenopausal Osteoporosis
Eastell, R. (1998) · New England Journal of Medicine · doi:10.1056/nejm199803123381107 · Cited by 615
Self-citationGenant, H. K., Grampp, S., Glüer, C. C., Faulkner, K. G., Jergas, M., Engelke, K., Hagiwara, S., & van Kuijk, C. (1994) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650091002 · Cited by 610
Cited by
Items 901–1,000 of 1,002
Indications to teriparatide treatment in patients with osteoporosis
Rizzoli, R., KRAENZLIN, M. E., & Lippuner, K. (2011) · Swiss Medical Weekly · doi:10.4414/smw.2011.13297 · Cited by 15
Tratamiento de la litiasis renal con bifosfonatos
Martín, M. A., de la Guardia, F. V. D., Pacheco, A. J., López‐León, V., Polo, M. Á. A., & Gómez, A. Z. (2007) · Archivos Españoles de Urología · doi:10.4321/s0004-06142007000700004 · Cited by 15
Prevention and Treatment of Postmenopausal Osteoporosis
Mahakala, A. R., Thoutreddy, S., & Kleerekoper, M. (2003) · Treatments in Endocrinology · doi:10.2165/00024677-200302050-00005 · Cited by 15
Solé, J. M. N., Gómez-Vaquero, C., Fiter, J., Vilaseca, D. R., Mateo, L., Rozadilla, A., Baurés, M. R., Valverde, J., & Escofet, D. R. (2002) · Annals of the Rheumatic Diseases · doi:10.1136/ard.61.1.73 · Cited by 15
Risedronate once monthly: a potential new regimen for the treatment of postmenopausal osteoporosis
Moro-Alvarez, J. (2008) · Clinical Interventions in Aging · doi:10.2147/cia.s2502 · Cited by 15
Kaštelan, D., Vlak, T., Lozo, P., Gradišer, M., Mijić, Š., Nikolic, T., Miškić, B., Car, D., Tajšić, G., Dušek, T., et al. (2010) · Endocrine Research · doi:10.3109/07435800.2010.505218 · Cited by 15
Analysis of 1-year Vertebral Fracture Risk Reduction Data in Treatments for Osteoporosis
Miller, P. D. (2003) · Southern Medical Journal · doi:10.1097/01.smj.0000067661.21765.fc · Cited by 15
ASHP Therapeutic Position Statement on the Prevention and Treatment of Osteoporosis in Adults
MacLaughlin, E. J., & Raehl, C. L. (2008) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp070302 · Cited by 15
Ibandronate: The Evolution of a Once-a-Month Oral Therapy for Postmenopausal Osteoporosis
Dempster, D. W., & Bolognese, M. A. (2006) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2005.09.004 · Cited by 15
Sebba, A. I. (2008) · Osteoporosis International · doi:10.1007/s00198-008-0802-0 · Cited by 15
Rosenblatt, M. (2003) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2003.18.6.1142 · Cited by 15
Bisphosphonate antifracture efficacy
Adami, S. (2007) · Bone · doi:10.1016/j.bone.2007.08.005 · Cited by 15
A rational approach to evidence gaps in the management of osteoporosis
Rosen, C. J., & Brown, S. A. (2005) · The American Journal of Medicine · doi:10.1016/j.amjmed.2005.06.002 · Cited by 15
Lan, Z., Lin, X., Xue, D., Yang, Y., Saad, M., & Jin, Q. (2024) · Clinical Orthopaedics and Related Research · doi:10.1097/corr.0000000000003204 · Cited by 14
Martino, G., Bellone, F., Vicario, C. M., Gaudio, A., Caputo, A., Corica, F., Squadrito, G., Schwarz, P., Morabito, N., & Catalano, A. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18158144 · Cited by 14
Cheng, J., ju, S., & Zhang, Z. (2023) · BMC Musculoskeletal Disorders · doi:10.1186/s12891-023-06253-9 · Cited by 14
Kendler, D. L., Ringe, J. D., Ste‐Marie, L., Vrijens, B., Taylor, E. B., & Delmas, P. D. (2009) · Osteoporosis International · doi:10.1007/s00198-009-0893-2 · Cited by 14
Economic implications of osteoporotic fractures in postmenopausal women
Patel, J. (2020) · The American Journal of Managed Care · doi:10.37765/ajmc.2020.88549 · Cited by 14
Risk of Upper Gastrointestinal Tract Events in Risedronate Users Switched to Alendronate
Ralston, S. H., Kou, T. D., Wick-Urban, B., Steinbuch, M., & Masud, T. (2010) · Calcified Tissue International · doi:10.1007/s00223-010-9401-0 · Cited by 14
Atmaca, A. A., & Gedik, O. (2006) · Advances in Therapy · doi:10.1007/bf02850205 · Cited by 14
Yoshida, M., Mori, A., Kotani, E., Oka, M., Makino, H., Fujita, H., Ban, J., Ikeda, Y., Kawamoto, T., Goto, M., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm101452x · Cited by 14
Bisphosphonate Treatment of Osteoporosis
Watts, N. B. (2003) · Humana Press eBooks · doi:10.1007/978-1-59259-278-4_23 · Cited by 14
Vacaciones terapéuticas en osteoporosis: estrategia en el tratamiento a largo plazo con bifosfonatos
Moro-Álvarez, M. J., Neyro, J. L., & Castañeda, S. (2015) · Medicina Clínica · doi:10.1016/j.medcli.2015.03.017 · Cited by 14
Combining Bisphosphonates with Hormone Therapy for Postmenopausal Osteoporosis
Fadanelli, M., & Bone, H. G. (2004) · Treatments in Endocrinology · doi:10.2165/00024677-200403060-00004 · Cited by 14
Alfacalcidol in men with osteoporosis: a prospective, observational, 2-year trial on 214 patients
Ringe, J. D., Farahmand, P., & Schacht, E. (2012) · Rheumatology International · doi:10.1007/s00296-012-2429-x · Cited by 14
Non-estrogen treatments for osteoporosis An evidence-based review
Bushardt, R. L., Turner, J. L., Ragucci, K. R., & Askins, D. G. (2006) · JAAPA · doi:10.1097/01720610-200612000-00006 · Cited by 14
Focus on Primary Care Postmenopausal Osteoporosis: An Update
Watts, N. B. (2000) · Obstetrical & Gynecological Survey · doi:10.1097/00006254-200012001-00001 · Cited by 14
Intravenous zoledronic acid for the treatment of osteoporosis
Lewiecki, E. M. (2008) · Current Osteoporosis Reports · doi:10.1007/s11914-008-0004-x · Cited by 14
Vertebral augmentation techniques for the treatment of vertebral compression fractures: A review
Vallejo, R., & Benyamin, R. M. (2010) · Techniques in Regional Anesthesia and Pain Management · doi:10.1053/j.trap.2010.06.004 · Cited by 13
Lebanese Guidelines for Osteoporosis Assessment and Treatment
Fuleihan, G. E., Baddoura, R., Awada, H., Okais, J., Rizk, P., & McClung, M. R. (2005) · Journal of Clinical Densitometry · doi:10.1385/jcd:8:2:148 · Cited by 13
¿Qué es el FRAX?: pros y contras
Vaquero, C. G., & Vilaseca, D. R. (2010) · Seminarios de la Fundación Española de Reumatología · doi:10.1016/j.semreu.2010.03.001 · Cited by 13
Piao, M.-S., Darwono, A. B., ZHU, K., & Zhao, K. (2019) · The International Journal of Spine Surgery · doi:10.14444/6027 · Cited by 13
Osteoporosis Diagnosis and Management
Pope, R. S., & Doback, J. (2020) · Physician Assistant Clinics · doi:10.1016/j.cpha.2020.09.009 · Cited by 13
Thompson, M., Pasquale, M. K., Grima, D. T., Möhrke, W., & Kruse, H. P. (2009) · Value in Health · doi:10.1111/j.1524-4733.2009.00666.x · Cited by 13
Pharmacological treatments for osteoporosis in very elderly people
Chua, W. M., Nandi, N., & Masud, T. (2011) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622311409972 · Cited by 13
Sergi, G., Pintore, G., Falci, C., Veronese, N., Berton, L., Perissinotto, E., Basso, U., Brunello, A., Monfardini, S., Manzato, E., et al. (2011) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-011-0341-1 · Cited by 13
Appelman‐Dijkstra, N. M., & Papapoulos, S. E. (2013) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2014.01.010 · Cited by 13
Management of osteoporosis with PTH: treatment and prescription patterns in Europe
Hosking, D. J., Alonso, C. G., & Brandi, M. L. (2008) · Current Medical Research and Opinion · doi:10.1185/03007990802645461 · Cited by 13
Self-citationBisphosphonates: Mechanisms of Action and Role in Osteoporosis Therapy
Santora, A. C., & Sharma, A. (2020) · Contemporary Endocrinology · doi:10.1007/978-3-319-69287-6_14 · Cited by 13
WHO fracture risk calculator (FRAX) in the assessment of obese patients with osteoporosis.
Franek, E., Wichrowska, H., Gozdowskı, D., & Puzianowska‐Kuźnicka, M. (2009) · PubMed · Cited by 13
Correlates of use of antifracture therapy in older women with low bone mineral density
Study, T. H. A., Ryder, K. M., Shorr, R. I., Tylavsky, F. A., Bush, A. J., Bauer, D. C., Simonsick, E. M., Strotmeyer, E. S., & Harris, T. B. (2006) · Journal of General Internal Medicine · doi:10.1111/j.1525-1497.2006.00468.x · Cited by 13
Kasturi, G. C., Cifu, D. X., & Adler, R. A. (2009) · PM&R · doi:10.1016/j.pmrj.2008.12.005 · Cited by 13
Assessment of oral bisphosphonate use in elderly patients with varying degrees of kidney function
Linnebur, S. A., & Milchak, J. L. (2004) · The American Journal of Geriatric Pharmacotherapy · doi:10.1016/j.amjopharm.2004.10.001 · Cited by 13
Osteoporosis Therapies: Bisphosphonates, SERMs, PTH, and New Therapies
Deal, C. L. (2005) · Clinical Reviews in Bone and Mineral Metabolism · doi:10.1385/bmm:3:2:125 · Cited by 13
Fracture Risk Assessment in Clinical Practice: T-scores, FRAX, and Beyond
Lewiecki, E. (2010) · Clinical Reviews in Bone and Mineral Metabolism · doi:10.1007/s12018-009-9054-6 · Cited by 8
The Effect of Risedronate on Posterior Lateral Spinal Fusion in a Rat Model
Gezici, A. R., Ergün, R., Gürel, K., Yılmaz, F., Okay, Ö., & Bozdoǧan, Ö. (2009) · Journal of Korean Neurosurgical Society · doi:10.3340/jkns.2009.46.1.45 · Cited by 13
Hodsman, A. B. (2001) · Peritoneal Dialysis International · doi:10.1177/089686080102103s44 · Cited by 13
Risedronate for prevention and treatment of osteoporosis in postmenopausal women
Recker, R. R., & Barger-Lux, J. (2005) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.6.3.465 · Cited by 13
Reginster, J., & Sarlet, N. (2006) · Treatments in Endocrinology · doi:10.2165/00024677-200605010-00003 · Cited by 13
Self-citationSchmidmaier, R., Hadji, P., Kern, P., Drey, M., Jakob, F. J., & Thomasius, F. E. (2023) · Osteologie/Osteology · doi:10.1055/a-2034-6086 · Cited by 12
di Filippo, L., Ulivieri, F. M., Nuti, R., & Giustina, A. (2023) · Endocrine · doi:10.1007/s12020-023-03551-z · Cited by 12
Eudy‐Byrne, R. J., Gillespie, W., Riggs, M. M., & Gastonguay, M. R. (2017) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-017-9551-z · Cited by 12
The Good and the Bad About the 2017 American College of Physicians Osteoporosis Guidelines
Lagari, V. S., Gavcovich, T. B., & Levis, S. (2017) · Clinical Therapeutics · doi:10.1016/j.clinthera.2017.11.008 · Cited by 12
Adjuvant drug-assisted bone healing: Part III – Further strategies for local and systemic modulation
Rothe, R., Schulze, S., Neuber, C., Hauser, S., Rammelt, S., & Pietzsch, J. (2019) · Clinical Hemorheology and Microcirculation · doi:10.3233/ch-199104 · Cited by 12
Pharmacological Therapies for Osteoporosis: A Bayesian Network Meta-Analysis
Shen, J., Ke, Z., Dong, S., Lv, M., Yuan, Y., Song, L., Wu, K., Xu, K., & Hu, Y. (2022) · Medical Science Monitor · doi:10.12659/msm.935491 · Cited by 12
Cohran, V. C., Cassedy, A. E., Hawkins, A. M., Bean, J. A., & Heubi, J. E. (2013) · Journal of Pediatric Rehabilitation Medicine · doi:10.3233/prm-130242 · Cited by 12
Guidelines for the detection and treatment of osteoporosis
Kocjan, T., Preželj, J., Pfeifer, M., Sever, M. J., Čokolič, M., & Zavratnik, A. (2013) · Slovenian Medical Journal · Cited by 12
McClung, M. R., Benhamou, C.-L., Man, Z., Tłustochowicz, W., Zanchetta, J., Eusebio, R. A., Balske, A., Matzkin, E., Olszynski, W. P., Recker, R. R., et al. (2012) · Calcified Tissue International · doi:10.1007/s00223-012-9668-4 · Cited by 12
Yoshida, M., Mori, A., Morimoto, S., Kotani, E., Oka, M., Notoya, K., Makino, H., Ono, M., Shirasaki, M., Tada, N., et al. (2011) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2011.02.001 · Cited by 12
Eekman, D. A., Vis, M., Bultink, I. E. M., Derikx, H. J., Dijkmans, B. A. C., & Lems, W. F. (2009) · BMC Musculoskeletal Disorders · doi:10.1186/1471-2474-10-86 · Cited by 12
Osteoporosis and fragility fractures: risk assessment, management and prevention
Walker, J. A. (2019) · Nursing Older People · doi:10.7748/nop.2019.e1153 · Cited by 12
Update on Approved Osteoporosis Therapies Including Combination and Sequential Use of Agents
Saul, D., & Drake, M. T. (2021) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2021.03.010 · Cited by 12
Albert, S. G., & Wood, E. M. (2021) · Endocrine Practice · doi:10.1016/j.eprac.2021.06.015 · Cited by 12
Komatsubara, S., Mori, S., Mashiba, T., Li, J., Nonaka, K., Kaji, Y., Akiyama, T., Miyamoto, K., Cao, Y., Kawanishi, J., et al. (2005) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2005.20.11.2066 · Cited by 12
Paliologo, T., Shimano, R. C., Shimano, A. C., Macedo, A. P., Falcai, M. J., & Issa, J. P. M. (2015) · Micron · doi:10.1016/j.micron.2015.07.002 · Cited by 12
Takakuwa, M., Iwamoto, J., Konishi, M., Zhou, Q., & Itabashi, K. (2010) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-010-0196-x · Cited by 12
Cosman, F., Borges, J. L. C., & Díaz Curiel, M. (2007) · Clinical Therapeutics · doi:10.1016/j.clinthera.2007.06.009 · Cited by 12
Ringe, J. D., Fardellone, P., Kruse, H. ‐., Amling, M., van der Geest, S. A. P., & Möller, G. (2009) · Drugs & Aging · doi:10.2165/00002512-200926030-00005 · Cited by 12
Clodronic Acid in the Treatment of Postmenopausal Osteoporosis
Tanakol, R., Yarman, S., Bayraktaroğlu, T., Boztepe, H., & l, F. A. (2007) · Clinical Drug Investigation · doi:10.2165/00044011-200727060-00005 · Cited by 12
Lane, N. E. (2007) · Current Opinion in Rheumatology · doi:10.1097/bor.0b013e32816a9436 · Cited by 12
Osteoporosis management in the new millennium
Wei, G. S., Jackson, J. L., Hatzigeorgiou, C., & Tofferi, J. K. (2003) · Primary Care Clinics in Office Practice · doi:10.1016/s0095-4543(03)00090-3 · Cited by 12
Shiraki, M., Kuroda, T., Nakamura, T., Fukunaga, M., Hosoi, T., Orimo, H., & Makino, K. (2006) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-005-0675-7 · Cited by 12
Gastrointestinal tolerability with ibandronate after previous weekly bisphosphonate treatment
Derman, R. J. (2009) · Clinical Interventions in Aging · doi:10.2147/cia.s5637 · Cited by 12
Understanding osteoclast formation and function: implications for future therapies for osteoporosis
Zaidi, M., Moonga, B. S., Sun, L., Epstein, S., Huang, C. L.-H., & Abe, E. (2003) · Current Opinion in Orthopedics · doi:10.1097/00001433-200310000-00007 · Cited by 12
Clinical use of instruments that measure peripheral bone mass
Blake, G. M., & Fogelman, I. (2002) · Current Opinion in Endocrinology & Diabetes · doi:10.1097/00060793-200212000-00010 · Cited by 12
PHARMACOLOGIC THERAPY FOR THE TREATMENT AND PREVENTION OF OSTEOPOROSIS
McClung, B. L., & McClung, M. R. (2001) · Nursing Clinics of North America · doi:10.1016/s0029-6465(22)02566-x · Cited by 12
Review of the safety and efficacy of risedronate for the treatment of male osteoporosis.
Bobba, R. S., & Adachi, J. D. (2007) · PubMed Central · Cited by 12
Dhesi, J. K., Allain, T. J., Mangoni, A. A., & Jackson, S. H. D. (2006) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2006.02612.x · Cited by 12
Schneeweiß, S. (2009) · Value in Health · doi:10.1111/j.1524-4733.2009.00607.x · Cited by 12
Pharmacological interventions for post-menopausal osteoporosis: an evidence-based approach
Compston, J. E. (2000) · British journal of rheumatology · doi:10.1093/rheumatology/39.12.1309 · Cited by 12
Alam, F., Alsaed, O. S., Abdulla, N., Abdulmomen, I., Lutf, A. Q. A., & Emadi, S. A. (2024) · Archives of Osteoporosis · doi:10.1007/s11657-024-01389-0 · Cited by 11
Clinical Strategies to Address Patients' Concerns in Osteoporosis Management with Bisphosphonates
Cole, R. E. (2011) · Postgraduate Medicine · doi:10.3810/pgm.2011.03.2271 · Cited by 11
Fan, T., Zhang, & Sen, S. (2013) · ClinicoEconomics and Outcomes Research · doi:10.2147/ceor.s39076 · Cited by 11
Tandon, V., Sharma, S., Mahajan, S., Mahajan, A., Khajuria, V., & Gillani, Z. (2014) · Journal of Mid-life Health · doi:10.4103/0976-7800.127788 · Cited by 11
Berto, P., Maggi, S., Noale, M., & Lopatriello, S. (2010) · Aging Clinical and Experimental Research · doi:10.1007/bf03324794 · Cited by 11
Nielsen, D. S., Langdahl, B. L., Sørensen, O., Sørensen, H. A., & Brixen, K. T. (2010) · Scandinavian Journal of Public Health · doi:10.1177/1403494810371243 · Cited by 11
Kinov, P. S., & Boyanov, M. (2012) · International Journal of Women s Health · doi:10.2147/ijwh.s18209 · Cited by 11
Bisphosphonate drug holidays: Can we recommend currently?
Tandon, V. R., Sharma, S., & Mahajan, A. (2014) · Journal of Mid-life Health · doi:10.4103/0976-7800.141186 · Cited by 11
Monitoring pharmacological therapy for osteoporosis
Lewiecki, E. (2010) · Reviews in Endocrine & Metabolic Disorders · doi:10.1007/s11154-010-9126-4 · Cited by 9
Is it ethical to use placebos in osteoporosis clinical trials?
Watts, N. B. (2004) · Current Osteoporosis Reports · doi:10.1007/s11914-004-0012-4 · Cited by 11
Wilton-Clark, M. S., Feasel, A. L., Kline, G. A., & Billington, E. O. (2020) · Archives of Osteoporosis · doi:10.1007/s11657-020-00809-1 · Cited by 11
Katayama, K., & Matsuno, T. (2008) · Clinical Drug Investigation · doi:10.2165/00044011-200828030-00002 · Cited by 11
Dane, C., Dane, B., Cetin, A., & Erginbaş, M. (2008) · Gynecological Endocrinology · doi:10.1080/09513590801895617 · Cited by 11
Treatment of osteoporosis: whom, how and for how long?
Dede, A. D., & Callan, M. F. C. (2018) · British Journal of Hospital Medicine · doi:10.12968/hmed.2018.79.5.259 · Cited by 11
Hodsman, A. B., Hanley, D. A., Watson, P. H., & Fraher, L. J. (2002) · Elsevier eBooks · doi:10.1016/b978-012098652-1.50177-3 · Cited by 11
Takada, J., Iba, K., Imoto, K., & Yamashita, T. (2007) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-006-0739-3 · Cited by 11
Obaid, H., Husamaldin, Z., & Bhatt, R. (2008) · Acta Radiologica · doi:10.1080/02841850802165776 · Cited by 11
Use of highly potent bisphosphonates in the treatment of osteoporosis
McClung, M. R. (2003) · Current Osteoporosis Reports · doi:10.1007/bf02686916 · Cited by 11
Miller, P. D. (2005) · Current Rheumatology Reports · doi:10.1007/s11926-005-0009-8 · Cited by 11
Pharmacological Management of Severe Postmenopausal Osteoporosis
Gaudio, A., & Morabito, N. (2005) · Drugs & Aging · doi:10.2165/00002512-200522050-00005 · Cited by 11
Metadata
- Authors
- Reginster, J.-Y., Minne, H. W., Sorensen, O. H., Hooper, M., Roux, C., Brandi, M. L., Lund, B., Ethgen, D., Pack, S., Roumagnac, I., & Eastell, R.
- Affiliations
- University of Liège (BE)
- The University of Sydney (AU)
- Hôpital Cochin (FR)
- University of Florence (IT)
- Procter & Gamble (United States) (US)
- University of Sheffield (GB)
- Venue
- Osteoporosis International
- Published
- 2000-01-01
- Volume
- 11
- Issue
- 1
- Pages
- 83-91
- ISSN
- 0937-941X (ISSN-L)
- 1433-2965
- OpenAlex
- W1526826623
- Cited by
- 1,580
- References
- 29
- Citations by year
- 2026: 14 · 2025: 17 · 2024: 19 · 2023: 25 · 2022: 26 · 2021: 31 · 2020: 38 · 2019: 30 · 2018: 36 · 2017: 27 · 2016: 44 · 2015: 50 · 2014: 47 · 2013: 69 · 2012: 66
- FWCI
- 78.35
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Osteoporosis International (publishedVersion)
- PubMed (publishedVersion)
- Florence Research (University of Florence) (submittedVersion)
- ORBi (University of Liège) (submittedVersion)
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Keywords
- risedronate, postmenopausal osteoporosis, vertebral fractures, fracture prevention, bisphosphonates, bone mineral density, non-vertebral fractures, calcium and vitamin D supplementation, gastrointestinal adverse effects, drug safety
- MeSH terms
- Risedronic Acid, Aged, Aged, 80 and over, Algorithms, Australia, Calcium Channel Blockers, Double-Blind Method, Europe, Female, Humans, Middle Aged, Etidronic Acid, Absorptiometry, Photon, Bone Density, Osteoporosis, Postmenopausal, Spinal Fractures, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.